ARGX Community Narratives

AnalystConsensusTarget's

Fair Value

Fair Value €845.01 9.4% undervalued

ARGX: Upcoming Phase 3 Readouts and Expanded Access Will Shape Future Outlook

kapirey's

Fair Value

Fair Value €686.43 11.6% overvalued

High-growth biotech compounding story if VYVGART becomes a multi-indication platform drug

AnalystLowTarget's

Fair Value

Fair Value €614.8 24.6% overvalued

Rising Pricing Pressures And Biosimilar Challenges Will Weaken Margins

About ARGX

Founded: 2008
Employees: 1863
CEO: Karen Massey
WebsiteView website: argenx.com

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Recent ARGX News & Updates

Announcement • Jun 03

Argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren’s Disease At EULAR 2026

Argenx SE announced the presentation of new data evaluating VYVGART (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) across autoimmune rheumatic diseases, including myositis and Sjogren’s disease, to be presented at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress from June 3-6, 2026, in London, UK. Myositis and Sjogren’s disease are both chronic, progressive autoimmune diseases that are generally more common in women than men. Myositis can cause serious and irreversible damage to muscles and organs, leading to a loss of independence and a significant burden for patients. Sjogren’s disease can cause dry eyes and mouth, chronic fatigue, and joint pain. It can also affect multiple organ systems and lead to nervous system complications. ALKIVIA+ is an ongoing open-label extension study that enrolled patients who completed the 24-week, double-blind, placebo-controlled Phase 2 ALKIVIA trial, including those who continued efgartigimod treatment and those who transitioned from placebo to efgartigimod. Results presented at EULAR are an interim analysis through Week 52. A key metric in ALKIVIA+ is Total Improvement Score (TIS). TIS is a composite index based on six core set measures, including muscle strength, physician and patient global assessments of disease activity, physical function, enzyme levels, and extramuscular activity. Higher TIS values reflect greater overall clinical improvement. Moderate and major improvement are defined as TIS =40 and =60, respectively. At 52 weeks, 37.5% of patients who had continuously received efgartigimod maintained their major TIS improvement from week 24. 33.3% of patients switching from placebo to efgartigimod achieved a similar major TIS improvement. Rates of moderate TIS improvement were also similar between the groups, at 75.0% and 66.7%, respectively. Sustained mean TIS benefit: Patients receiving continuous efgartigimod maintained clinically meaningful improvement through 52 weeks, with a mean TIS of 52.19. Patients who switched from placebo to efgartigimod achieved comparable improvement, with a mean TIS of 49.62 at week 52. The safety profile was consistent over the course of the study, with no increase in adverse events with longer exposure. These results further support the mechanistic relevance of FcRn blockade in myositis, providing further evidence that pathogenic autoantibodies are the underlying driver of disease. Topline results from the Phase 3 ALKIVIA study are expected in the third quarter of 2026. RHO+, a 48-week open-label extension study, evaluated patients with Sjogren's disease who continued to receive efgartigimod, and those who transitioned from placebo to efgartigimod after completing the 24-week double-blind treatment period of the Phase 2 RHO study. Response to efgartigimod was assessed using the Composite of Relevant Endpoints for Sjogren’s Syndrome (CRESS), a composite endpoint designed to capture overall treatment benefit across multiple clinical domains, including disease activity as measured by ClinESSDAI. Patients in the efgartigimod arm were switched to biweekly dosing based on ClinESSDAI response. Patients in the efgartigimod arm switching to biweekly dosing experienced maintenance of response on clinical measures. Patients in the placebo arm switching to efgartigimod experienced improvements in ClinESSDAI and increased CRESS response. At week 72, median ClinESSDAI scores were low in both groups: 2.5 in the efgartigimod arm and 2.0 in patients who transitioned from placebo to efgartigimod. Low disease activity is indicated by a ClinESSDAI score of less than 5. Cross-indication analysis of efgartigimod data across rheumatology studies underscores consistent safety profile in large patient population.

Recent updates

No updates

argenx SE Stock Price

ARGX Share Price Performance

ARGX Community Narratives

ARGX: Upcoming Phase 3 Readouts and Expanded Access Will Shape Future Outlook

High-growth biotech compounding story if VYVGART becomes a multi-indication platform drug

Rising Pricing Pressures And Biosimilar Challenges Will Weaken Margins

High-growth biotech compounding story if VYVGART becomes a multi-indication platform drug

AI Collaboration And Aging Trends Will Expand Autoimmune Biologics Markets

ARGX: Upcoming Phase 3 Readouts and Expanded Access Will Shape Future Outlook

Rising Pricing Pressures And Biosimilar Challenges Will Weaken Margins

Trending Discussion

Recently Updated Narratives

High-growth biotech compounding story if VYVGART becomes a multi-indication platform drug

ARGX: Expanded gMG Label And Myositis Readouts Will Drive Future Repricing Potential

ARGX: Expanded Neuromuscular Indications Will Support Future Earnings Power

Snowflake Analysis

argenx SE Key Details

About ARGX

Recent ARGX News & Updates

Argenx Unveils Vyvgart Data for Myositis and Sjogren’s at EULAR 2026

Argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren’s Disease At EULAR 2026

ARGX: Expanded gMG Label And Myositis Readouts Will Drive Future Repricing Potential

Recent updates

argenx SE Competitors

UCB

Financière de Tubize